Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
SVRA
Stock Latest News
The Fly
Savara says FDA files BLA for Molbreevi
1d ago
SVRA
Premium
The Fly
Savara announces BLA for Molbreevi filed for review by FDA
1d ago
SVRA
Premium
Company Announcements
Savara Advances Pediatric aPAP Trial With Inhaled Molgramostim, Extending Its Rare Lung Disease Reach
2d ago
SVRA
Premium
Company Announcements
Savara Enters New Material Definitive Agreement and Obligation
25d ago
8K
SVRA
Premium
Ratings
Savara (SVRA): Advancing MOLBREEVI Toward Likely FDA Approval and Blockbuster Rare Disease Potential
1M ago
SVRA
Premium
Company Announcements
Savara Highlights Autoimmune PAP Burden in Updated Presentation
1M ago
8K
SVRA
Premium
Ratings
Savara (SVRA): Molbreevi De-Risking and Enhanced aPAP Market Visibility Support Higher Target and Buy Rating
2M ago
SVRA
Premium
The Fly
Savara price target raised to $10 from $8 at H.C. Wainwright
2M ago
SVRA
Premium
Ratings
Savara (SVRA): Buy Rating on High MOLBREEVI Approval Odds and Blockbuster Commercial Potential
2M ago
SVRA
Premium
The Fly
Savara resubmits Molbreevi BLA to the FDA
2M ago
SVRA
Premium
The Fly
Savara announces EPO intention to grant Molbreevi patent application
2M ago
SVRA
Premium
Ratings
Savara’s MOLBREEVI: A Promising Solution for aPAP with Blockbuster Potential
2M ago
SVRA
Premium
The Fly
Savara rumor highlighted in Betaville blog
3M ago
SVRA
Premium
The Fly
Savara issues patent for Molbreevi from European Patent Office
3M ago
SVRA
Premium
Ratings
Savara’s MOLBREEVI: Promising Potential in APAP Market with Strategic Expert Engagement
3M ago
SVRA
Premium
Company Announcements
Savara Inc. Reports Q3 2025 Financial Results
3M ago
SVRA
Premium
The Fly
Savara price target raised to $9 from $8 at Oppenheimer
3M ago
SVRA
Premium
Ratings
Savara’s Strategic Positioning and Market Readiness for Molbreevi’s Potential Launch
3M ago
SVRA
Premium
Ratings
Savara’s MOLBREEVI: Strong Phase 3 Data and Financial Positioning Signal High Approval Likelihood and Market Potential
3M ago
SVRA
Premium
The Fly
Savara price target lowered to $10 from $11 at Citizens JMP
3M ago
SVRA
Premium
The Fly
Savara reports Q3 EPS (14c), consensus (13c)
3M ago
SVRA
Premium
Market News
Savara Hit with Class Action Over Molbreevi Misrepresentations
4M ago
SVRA
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
